ImmuneOnco secures 25 million RMB in pre-A round of fund-raising from Shanghai Zhangke Lingyi Investment Corporation
ImmuneOnco Biopharmaceuticals Co., Ltd, an early-stage immunotherapy company dedicated to development and commercialization of novel cancer immunotherapy products, today announced closing of first round fund-raising in pre-A round as of the amount of 25 million RMB from Shanghai Zhangke Lingyi Investment Corporation. “We are delighted to have Zhangke Lingyi to join us with which we will advance our projects to the next level of development”, commented Dr. Wenzhi Tian, Founder and Chairman of ImmuneOnco. “We believe with our expertise both in antibody technology and immunology, we will be able to build an attractive project portfolio that will meet unmet medical need to patients with cancer if successfully developed”.
“Tumor immunotherapy is the hotspot in drug development, we are pleased to set up a tight collaboration with Dr. Tian who has much experience in antibody drug development. We believe our collaboration will definitely generate mutual benefit to both sides”, said Mr. Xiaoyong Yu, Chairman and CEO of Zhangke Lingyi.